Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Daiichi Sankyo Announces Delay in Flu Vaccine Shipment Due to Possible Contamination
September 26, 2011
- Ajinomoto Files Suit over Actonel Generic Seeking Suspension of Sales
September 26, 2011
- Trans Genic Files Patent Application for Antibody against Novel Lung Cancer Marker
September 26, 2011
- US FDA Completes Review of Protocol for PIII Trial of Collategene: AnGes MG
September 26, 2011
- Astellas: OAB Treatment Betanis Tablets
September 26, 2011
- Ono/Astellas: Once-Every-Four-Weeks Formulation of Recalbon, Bonoteo
September 26, 2011
- MTPC, Janssen Pharma Launch RA Treatment Simponi
September 26, 2011
- Vibativ Approved in Europe for Treatment of Nosocomial Pneumonia: Astellas
September 26, 2011
- Takeda Aiming to Make Comeback in Diabetes Market
September 25, 2011
- Novartis Grows 7% Driven by New Products: President Mitani
September 22, 2011
- PIII Trial for Brain Function Imaging Agent Starts: Nihon Medi-Physics
September 21, 2011
- Nichi-Iko to Postpone M&A of Nichi-iko Pharma Factory Until June 2012
September 21, 2011
- Kaken President Onuma Targets ¥20 Billion in Operating Profits in 2015
September 21, 2011
- Kowa Yakuhin Sets Up Private Electric Generators as Part of Disaster Measures
September 20, 2011
- Sitagliptin Receives Approval for Use in Combination with Insulin: MSD, Ono
September 20, 2011
- CellCept Obtains Approval for Additional Pediatric Dosage: Chugai
September 20, 2011
- Janssen Obtains Additional Indication for Treatment-Naïve MM
September 20, 2011
- Takeda Initiates Domestic PIII Trials for Successor to Takepron
September 20, 2011
- Sandoz to Use Its Unique Anticancer Drug Container for More Anticancer Drugs
September 19, 2011
- Nichi-Iko, Pfizer Apply for Add’l Indication for Generic Cisplatin Using Data from Public Domain
September 19, 2011
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…